Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab  
1/9/2012 6:35:48 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Micromet (Nasdaq: MITI) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to expand development of the Company’s lead product candidate blinatumomab in patients with acute lymphoblastic leukemia (ALL) and various sub-types of lymphoma. Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.